LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis-Reference-Cited by-同舟云学术

LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis

Published:2019-12-20 Issue:1 Volume:21 Page:1-8
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Song Yeong Wook¹²^ORCID,Park Yong-Beom³,Kim Jinseok⁴

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

2. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, South Korea

3. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

4. Division of Rheumatology, Jeju National University Hospital, Jeju, South Korea

Funder

Ministry of Science, ICT and Future Planning

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1701650

Reference50 articles.

1. Rheumatoid arthritis

2. The clinical features of rheumatoid arthritis

3. World Health Organization. Chronic rheumatic conditions [Internet]. 2019 [cited 2019 Aug 8]. Available from: https://www.who.int/chp/topics/rheumatic/en/

4. The use of TNF-α blocking agents in rheumatoid arthritis: an overview

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort;Modern Rheumatology;2024-03-05